Biologic Activity and Biotechnological Development of Natural ProductsView this Special Issue
Research Article | Open Access
Mohammad Faseleh Jahromi, Juan Boo Liang, Yin Wan Ho, Rosfarizan Mohamad, Yong Meng Goh, Parisa Shokryazdan, James Chin, "Lovastatin in Aspergillus terreus: Fermented Rice Straw Extracts Interferes with Methane Production and Gene Expression in Methanobrevibacter smithii", BioMed Research International, vol. 2013, Article ID 604721, 10 pages, 2013. https://doi.org/10.1155/2013/604721
Lovastatin in Aspergillus terreus: Fermented Rice Straw Extracts Interferes with Methane Production and Gene Expression in Methanobrevibacter smithii
Lovastatin, a natural byproduct of some fungi, is able to inhibit HMG-CoA (3-hydroxy-3methyl glutaryl CoA) reductase. This is a key enzyme involved in isoprenoid synthesis and essential for cell membrane formation in methanogenic Archaea. In this paper, experiments were designed to test the hypothesis that lovastatin secreted by Aspergillus terreus in fermented rice straw extracts (FRSE) can inhibit growth and CH4 production in Methanobrevibacter smithii (a test methanogen). By HPLC analysis, 75% of the total lovastatin in FRSE was in the active hydroxyacid form, and in vitro studies confirmed that this had a stronger effect in reducing both growth and CH4 production in M. smithii compared to commercial lovastatin. Transmission electron micrographs revealed distorted morphological divisions of lovastatin- and FRSE-treated M. smithii cells, supporting its role in blocking normal cell membrane synthesis. Real-time PCR confirmed that both commercial lovastatin and FRSE increased () the expression of HMG-CoA reductase gene (hmg). In addition, expressions of other gene transcripts in M. smithii. with a key involvement in methanogenesis were also affected. Experimental confirmation that CH4 production is inhibited by lovastatin in A. terreus-fermented rice straw paves the way for its evaluation as a feed additive for mitigating CH4 production in ruminants.
The formation of isoprenoid chains is a key component of membrane phospholipid synthesis in Archaea. This pathway requires the production of mevalonic acid from 3-hydroxy-3methyl glutaryl CoA catalyzed by the enzyme HMG-CoA reductase, a critical rate-limiting step shared in common with cholesterol biosynthesis in humans (Figure 1). Lovastatin is a natural polyketide synthesized by Aspergillus terreus and Pleurotus ostreatus (oyster mushroom), where it may occur at concentrations as high as 2.8% dry weight . Lovastatin prescribed at a dosage of 80 mg daily can dramatically reduce cholesterol levels by 40% simply through the inhibition of HMG-CoA reductase activity. Through interference with membrane synthesis (Figure 1), lovastatin can inhibit the growth of methanogenic Archaea in the rumen without adverse effects on other cellulolytic bacteria  and, in this way, mediates reduction in methane (CH4) release into the environment. However, the high cost of lovastatin preempts its use as a feed additive in the mitigation of ruminal CH4 production. Another approach that may be economically viable is to incorporate A. terreus as a feed supplement and inhibitor of methanogenic Archaea that produces methane in the process of methanogenesis (Figure 2). Furthermore, since A. terreus is a known producer of cellulolytic enzymes [3–5], it complements the degradation of lignocellulose components in the rumen enhance feed conversion efficiency. This paper describes a series of experiments to test the hypothesis that lovastatin generated by A. terreus fermentation of rice straw (fungal treated rice straw extracts or FRSE) inhibits the growth and methanogenesis by Methanobrevibacter smithii (DSM 861), a gastrointestinal methanogen similar to the dominant species in the rumen. The molecular mechanism for this effect was also elucidated by real-time PCR.
2. Materials and Methods
2.1. Substrate, Microorganism, and Spore Suspension
Rice straw (RS) was collected from the local rice fields in the state of Selangor, Malaysia. The material was dried and ground to uniform size (No. 6 mesh) and stored in plastic bags at 4°C for later use as a substrate.
A. terreus ATCC 74135, obtained from American Type Culture Collection (ATCC), was maintained on potato dextrose agar (PDA) slants at 25°C for 7 days, stored at 4°C, and subcultured every two weeks. Spore suspension was prepared in 0.1% Tween-80 solution in approximately 107 spores/mL concentration.
2.2. Solid-State Fermentation
Solid state fermentation of RS was carried out in 2 L Erlenmeyer flasks. About 200 grams of RS, 200 mL distilled water (containing 1% urea) were added to give moisture content of approximately 50%. The flasks were plugged with cotton-wool and autoclaved at 121°C for 15 min prior to inoculate with 40 mL of an A. terreus spore suspension (containing 107 spores/mL). A sample was fermented at 25°C for 8 days, conditions which had previously been found to be optimal . At the end of fermentation, the sample was dried at 60°C for 48 h.
2.3. Preparation of FRSE
For preparation of FRSE, 200 g of the fermented rice straw was mixed with 1.5 L of methanol and shaken for 2 h at room temperature. The solid samples were removed from the suspension by vacuum filtration (0.45 μm pore size, Pall Corporation, Ann Arbor, MI). Methanol was removed by rotary evaporation at 45°C (Eppendorf, USA), and the solid residual or FRSE was used in the further experiments.
2.4. Lovastatin Quantification by HPLC
The concentration of lovastatin in the FRSE was quantified using HPLC (Waters, USA, 2690) and an ODS column of Agilent ( mm i.d., 5 μm). The mobile phase consisted of acetonitrile and water (70 : 30 by volume) containing 0.5% acetic acid. The UV photo diode array (PDA) detection range was set from 210 to 400 nm, and lovastatin was detected at 237 nm. The sample injection volume was 20 μL, and the running time was 15 min. Different concentrations of lovastatin (mevinolin, 98%, HPLC grade, sigma, M2147) were used as standard.
2.5. Microorganism and Anaerobic Microbial Culture
Methanobrevibacter smithii DSM 861 used in this study was obtained from the German Resource Centre for Biological Material (DSMZ, Germany). The Balch medium 1 was used for the growth of M. smithii with some modification on it containing 0.45 g/L of K2HPO4, 0.45 g/L of KH2PO4, 0.45 g/L of (NH4)2SO4, 0.9 g/L of NaCl, 0.12 g/L of CaCl2·2H2O, 0.19 g/L of MgSO4·7H2O, 2.5 g/L of NaHCO3, 2.0 g/L of Trypticase, 2.0 g/L of yeast extract, 2.5 g/L of sodium acetate, 2.5 g/L of sodium formate, g/L of coenzyme M (sodium 2-mercaptoethane-sulfonate), 0.5 g/L of cysteine·HCl, 0.5 g/L of Na2S·9H2O, and 0.001 g/L resazurin (pH 6.9). Vitamin and trace mineral solutions were added according to Balch et al. , and a VFA mixture was added according to Lovley et al. . The mixture was flushed with CO2, and approximately 10 mL of medium was transferred into 50 mL serum bottles under anaerobic conditions. The bottles were closed by rubber stoppers and aluminum seals and autoclaved in 121°C for 15 min. Lovastatin in final concentrations of 1, 10, and 50 μg/mL and FRSE in final concentration of 10, 100, and 500 μg/mL were filter-sterilized using 0.2 μm sterile syringe filters (Pall/Gelman, East Hills, NY, USA) and added into the medium after autoclaving. The samples were inoculated with 5% of a 72 h culture of M. smithii. The gas phase in each bottle was exchanged with an 80% H2-20% CO2 gas mixture at 100 kPa. The bottles were incubated at 39°C for 72 h. Growth was monitored from the optical density at 620 nm.
2.6. Methane Determination
The concentration of CH4 in the headspace gas phase was determined with an Agilent 6890 Series Gas Chromatograph (Wilmington, DE, USA). Separation of the gases was achieved using an HP-Plot Q column (30 m × 0.53 mm × 40 μm) (Agilent Technologies, Wilmington, DE, USA) with N2 as the carrier gas with a flow rate of 3.5 mL/min (MOX, Kuala Lumpur, Malaysia). The isothermal oven temperature was 50°C, and separated gases were detected using a thermal conductivity detector. Methane was eluted in 4 min. Calibration used standard gas prepared by Scott Specialty Gases (Supelco, Bellefonte, PA, USA), which contain 1% of CH4, CO, CO2, O2, and H2 in N2.
2.7. RNA Extraction and Gene Expression
Cells from two milliliters of culture were harvested by centrifugation at 10,000 rpm for 2 min at 4°C and directly used for RNA extraction. RNA was extracted using the RiboPure Bacteria RNA Isolation kit (AMBION, AM1925, Austin, TX, USA) according to the manufacturer’s protocol and reverse transcribed into cDNA using First Strand cDNA synthesis Kit according to the manufacturer’s instructions (Maxime RT-PCR Kit, iNtRON, Germany). In the next step, Real-time PCR was performed with the BioRad CFX96 Touch (Bio-Rad, USA) using optical grade plates. The PCR reaction was performed on a total volume of 25 μL using the iQSYBR Green Supermix (BioRad, USA). Each reaction included 12.5 μL SYBR Green Supermix, 1 μL of each Primer, 1 μL of cDNA samples, and 9.5 μL H2O. All real-time PCRs were performed in duplicate. Primers used in this study are shown in Table 1. 16S rRNA was used as reference gene . The method was used for determination of relative gene expression . Results of the real-time PCR data were represented as CT values of the threshold cycle number at which amplified product was first detected. ΔCT is difference in CT value of the target gene from the CT value of the reference gene (16S rRNA). ΔΔCT is ΔCT of treatment samples (lovastatin and FRSE) minus ΔCT of the untreated control. Data is presented as fold change expression in the target gene of a treatment sample compared to the normal sample.
2.8. Transmission Electron Microscopy (TEM)
The procedure of sample preparation of Hayat  with minor modified  by the Electron Microscopy Unit, Institute of Bioscience, Universiti Putra, Malaysia, was used for the TEM study. A Hitachi H-7100 (Japan) transmission electron microscope was used.
2.9. Statistical Analysis
All of the experiments were performed in triplicate. Data were analyzed as a completely randomized design (CRD) using the general linear model (GLM) procedure of SAS 9.2 . All multiple comparisons among means were performed using Duncan’s new multiple range test ().
3.1. Purity of Lovastatin
The purity of lovastatin in FRSE was compared with the commercially available form by HPLC. Figure 3 shows that commercial lovastatin was >98% in the lactone form. In contrast, the yield of lovastatin was 97 mg/g dry matter in FRSE, and approximately 75% of this was in the bioactive hydroxyacid form (73 mg/g DM). More information about production of lovastatin by A. terreus in solid state fermentation was published in our previous paper . To evaluate the effectiveness of the commercial and FRES lovastatin, 3 dilutions representing 1, 10, and 50 μg/mL of commercial lovastatin and 10, 100, and 500 μg/mL of FRSE (contain lovastatin) were used to investigate the biological activity of lovastatin on growth morphology, methane production, and gene transcript activity.
3.2. Microbial Growth and CH4 Production
Treatment with commercial and FRSE lovastatin significantly () inhibited the growth of M. smithii (Figure 4). Inhibition by commercial lovastatin at 10 and 50 μg/mL was similar to that of 100 and 500 μg/mL FRSE, respectively. At the same concentration of total lovastatin, the growth inhibitory effect of FRSE on M. smithi was much stronger than when commercial lovastatin was used alone.
Commercial lovastatin and FRSE also inhibited CH4 production after 72 h of incubation (Figure 5). At the same concentration of total lovastatin, CH4 production in the FRSE treatments was lower than treatments containing commercial lovastatin. There was no significant difference in CH4 production by 10 μg/mL commercial lovastatin and 10 μg/mL FRSE (equivalent to 1 μg/mL total lovastatin) while CH4 was not detected in cultures containing 500 μg/mL FRSE (Figure 5).
3.3. Microbial Morphology
Following growth with commercial lovastatin or FRSE, the morphology of M. smithii was greatly altered (Figure 6). The lines of cell division in M. smithii for the control samples (Figures 6(a) and 6(b)) displayed symmetrical cell division, while mitotic figures in treated samples were off-centered resulting in aberrant division figures.
3.4. Gene Expression
To obtain some insight into the mechanism of decreased CH4 production in M. smithii, real-time PCR was used to analyse the effect of commercial lovastatin and FRSE on expression of some of the key genes involved in the methanogenic pathway (Figure 2). Since little growth and CH4 are produced by M. smithii in the high concentration of lovastatin and FRSE and it is not possible to extract sufficient quantity of RNA in these samples, RNA was extracted only from control and two lower levels of treatments. Both commercial lovastatin and FRSE significantly increased the expression of HMG-CoA reductase gene (hmg) (). Fold change in expression of this gene in FRSE treated cells was higher than those treated with commercial lovastatin (Figure 7(a)), and the maximal change caused by the 50 μg/mL FRSE was a 9-fold increase.
(a) Effects of treatments on expression of HMG-CoA reductase gene, hmg ( )
(b) Effect of treatments on expression of methylene-H4MPT dehydrogenase gene, hmd ( )
(c) Expression of alcohol dehydrogenase gene, adh ( )
(d) Effects of treatments on expression of F420-dependent NADP reductase gene, fno ( )
(e) Effects of treatments on expression of methyl-H4MPT : coenzyme M methyltransferase gene, mtr ( )
(f) Expression of methyl coenzyme-M reductase gene subunit A, mcrA ( )
(g) Effects of treatments on expression of methanol:cobalamin methyltransferase gene, mta ( )
The FRSE treatments, but not commercial lovastatin, also had a significant effect on expression of methylene-H4MPT dehydrogenase gene (hmd) that encodes the enzyme for conversion the methenyl-H4MPT into methylene-H4MPT (Figure 2). Similarly, with commercial lovastatin and FRSE reduced the expression of alcohol dehydrogenase gene (adh), this reduction was not significant () (Figure 7(c)). Treatments containing 10 μg/mL Lovastatin, 10 μg/mL and 50 μg/mL FRSE significantly () reduced the expression of F420-dependent NADP reductase gene (fno) in M. smithii (Figure 7(d)). L-lovastatin and FRSE increased the expression of methyl-H4MPT : coenzyme M methyltransferase gene (mtr) (Figure 7(e)). This gene produces the enzyme for the transfer of methyl group from methyl-H4MPT to HS-COM . Methyl coenzyme-M reductase (mcr) is the last enzyme in the methanogenesis pathway. The effect of lovastatin and FRSE on expression of this gene is shown in Figure 7(f). The result shows that lovastatin has no effect on the expression of this gene, but FRSE at both levels increased the expression of this gene in M. smithii (). Methanol : cobalamin methyltransferase gene (mta) is the gene for encoding of methanol : cobalamin methyltransferase that catalyses the conversion of methanol into COR-CH3 and production of CH4 in the process of methanogenesis. Both lovastatin and FRSE significantly increase the expression of this gene in M. smithii () (Figure 7(g)). The enhancement effect of FRSE on expression of this gene was higher than L-lovastatin.
Lovastatin is an effective therapy in the treatment of hypercholesterolemia because of its ability to inhibit HMG-CoA reductase activity, a key enzyme involved in cholesterol synthesis . Because of this, it is easy to ignore the fact that generic fungal statins have evolved to allow producer strains to gain a competitive survival advantage in complex ecological communities by interfering with the assembly of isoprenoid chains required for membrane phospholipid synthesis . In this way, statin-producing fungi can arrest the growth rates of susceptible strains  by interfering with cell wall formation and arresting cellular division . To test whether such a strategy could be used for the reduction of methane production by ruminants, it was necessary to show firstly that rice straws fermented with a representative statin-producing fungal strain of Aspergillus terreus, was capable of synthesizing biologically active lovastatin. HPLC confirmed that while commercial lovastatin existed primarily in a biologically inactive lactone (L) form, the biologically active hydroxyacid or H-form predominated in FRSE (Figure 3).
In the second stage, it was necessary to demonstrate that the lovastatin in FRSE was able to exert a biological impact on growth and cell membrane assembly in the target experimental methanogen—M. smithii. As shown in Figure 4, growth rates of M. smithii were inhibited by both commercial lovastatin and FRSE. At the same time, electron micrographs of M. smithii showed abnormal formation of cell membranes in mitosis, presumably caused by interference in the synthesis of isoprenoid building blocks. Although both treatments significantly () inhibited the growth of M. smithii, the growth inhibitory effect of FRSE on M. smithi was much stronger than when control L-lovastatin was used alone. It is likely that this could have been the consequence of having to convert the lactone form to the hydroxy form of lovastatin before the inhibition of HMG-CoA reductase can occur in M. smithii.
Commercial lovastatin contains 2% of the active H-form of lovastatin, so their titrations of 1, 10, and 50 ug/mL represent 0.02, 0.20, and 1 ug H-form per mL. The FRSE contains 7.3% H-form of lovastatin and 10, 100, and 500 ug DM/mL FRSE are actually 0.73, 7.3, and 36.5 ug/mL H-lovastatin. Thus, their lowest concentration of FRSE is similar in H-form content with their highest commercial lovastatin concentration, which was much more inhibitory in the experiments shown in both Figures 4 and 5. Similarly, in Figure 4, 1 ug/mL of the commercial form appears to be roughly equivalent to 10 ug/mL of FRSE. In Figure 5, 10 ug/mL of the commercial form appears to be roughly equivalent to 10 ug/mL of FRSE. This would seem to suggest that on a total (H + L-form) lovastatin basis, the FRSE appears to be roughly equivalent to possibly 10-fold more active.
It is important to note that this activity of lovastatin against a methanogen operates differently from its antiproliferative activity against eukaryote cells. Damage of the human cell division by lovastatin has been reported in a previous study . Van de Donk et al.  showed that lovastatin negatively affected membrane structure in the myeloma plasma cells and reduced the plasma cell viability, but this was due to the induction of apoptosis and inhibition of proliferation and probably a pleiotropic effect of statins on nuclear receptors in eukaryote cells . Lovastatin interference with nuclear receptors can act synergistically with its ability to inhibit polyisoprenylation and subsequent downstream distortion of intracellular matrix reorganization during cell division [21, 23, 24]. The antiproliferative activity of statins had found increasing use as anticancer drugs in cancer therapy [25, 26].
Microbial diversity in the rumen enables ruminants to convert lignocellulosic materials into useful nutrients such as VFA and microbial protein for the host animal. This is complemented by another group of microorganisms, the methanogenic Archaea which coexists within the rumen ecosystem by converting H2 and CO2 into CH4, a greenhouse gas which has been a serious contender for global warming and climate change. Mitigation of rumen CH4 production has two advantages: reduction of dietary energy loss, thus improving the efficiency of nutrient utilization by the host animal, and mitigation of enteric CH4 production. Both commercial lovastatin and FRSE significantly inhibited CH4 production, growth, and cell division of M. smithii. Other strategies for mitigation of CH4 production in the rumen ecosystem have been extensively researched but with limited success. The idea of applying lovastatin to suppress methanogenesis in methanogenic Archaea  has been tested previously. These authors reported that commercial lovastatin inhibited growth of methanogenic Archaea without adversely affecting other cellulolytic bacteria. In practical terms, it is simply uneconomical to use lovastatin as a feed additive for reduction of methanogenesis in ruminants under farm conditions.
A major difference between Archaea and other microorganisms lies in the structure of their cell membrane. The lipid arm of phospholipids in Archaea is made up of branched isoprenoid, but in other microorganisms, it is fatty acid . The process of isoprenoid and phospholipid biosynthesis in Archaea (Figure 1 in dotted-line markers) share similarities with cholesterol biosynthesis in eukaryotic cells (Figure 1 in solid-line markers) with HMG-CoA reductase as a key enzyme in both pathways, primarily to convert 3-hydroxy-3-3methylglutaryl-CoA (HMG-CoA) to mevalonic acid. Figure 7(a) showed a significant increase in HMG-CoA reductase gene (hmg) transcripts in M. smithii following lovastatin exposure, a result consistent with increased cellular need for more HMG-CoA reductase enzyme to process a buildup of HMG-CoA because of lovastatin-mediated competitive inactivation of HMG-CoA reductase. It is also evident from Figure 7(a) that H-lovastatin in FRSE was more effective than commercial L-lovastatin in generating a buildup of hmg gene transcripts. This is the first report of statins on expression of HMG-CoA reductase gene in Archaea and complements other in vitro and in-vivo experiments showing increases (seven fold after atorvastatin treatment) and decreases (two-fold after simvastatin treatment) in HMG-CoA reductase gene activation  in eukaryote cells. As well, enhancement of the relative expression of hmg genes and protein production involved in cholestrol biosynthesis by lovastatin have also been reported for many other systems [28–32]. Essentially, the mode of action of FRSE lovastatin on HMG-CoA reductase in Archaea is similar to its effect in animal cells.
While the experimental evidence so far supports the working hypothesis that interference of the isoprenoid synthetic pathway by lovastatin inhibition of HMG CoA synthetase is primarily responsible for reduced cell growth and decreased methane production, it is likely that the pleiotropic consequences of lovastatin on eukaryote cells in terms of its anti-proliferative and antimetabolic activity may have similar effects on other metabolic pathways in Archaea. For instance, quantitative proteomic analysis has revealed that lovastatin induced perturbation in multiple cellular pathways in HL-60 cells . In the case of Archaea, methane production could also be affected by lovastatin by interference in its synthetic pathway. To assess this possibility, the biosynthetic pathway of methanogenesis is summarized in Figure 2. Methyl H4MPT is a pivotal component in this pathway because its synthesis is vital for the production of acetyl-CoA, a key element in cellular processes and metabolism . We selected 3 genes—hmd, adh, and fno that are involved in the synthesis of Methyl H4MPT and 3 others responsible for methane synthesis—mtr, mcr, and mta for real-time PCR assays using the same RNA message transcripts from cultures sampled for hmg analysis. The results in Figure 7 show that hmd (B), adh (C), and fno (D) gene transcripts were all depressed in M. smithii following exposure to lovastatin. We propose that lovastatin interference of isoprenyl precursor synthesis has caused an increased buildup of acetyl-CoA in the metabolic pool resulting in feedback suppression of genes engaged in the synthesis of Methyl H4MPT. Surprisingly, despite a drop in overall CH4 production in the cultures, there was an increased expression in the three genes (mtr, mcr, and mta) responsible for CH4 synthesis. We propose that this anomaly is not spurious but represents the transcriptome of M. smithii cells that are not dividing because they have been adversely affected by lovastatin. In these cells, mtr, mcr, and mta gene transcripts (Figures 7(e), 7(f), and 7(g), resp.) are working in cohort to dissipate intracellular pools of Methyl-H4MPT.
In conclusion, we have shown that sufficient levels of biologically active H-lovastatin are produced in rice straws fermented by A. terreus, and fermented rice straw extracts are able to disrupt cell wall formation in the chosen rumen test methanogen M. smithii. This disruption is associated with decreased CH4 production driven in part by interference with isoprenyl synthesis and also through pleiotropic interference of lovastatin in other metabolic pathways. The incorporation of FRSE as a feed additive for ruminants appears to be an economically viable and environmentally sustainable strategy to mitigate CH4 production.
This study was supported by the Fundamental Research Grant Scheme (FRGS 1/2010 UPM) of the Department of Higher Education, Malaysia.
- J. Alarcón, S. Águila, P. Arancibia-Avila, O. Fuentes, E. Zamorano-Ponce, and M. Hernández, “Production and purification of statins from Pleurotus ostreatus (Basidiomycetes) strains,” Zeitschrift fur Naturforschung, vol. 58, no. 1-2, pp. 62–64, 2003.
- T. L. Miller and M. J. Wolin, “Inhibition of growth of methane-producing bacteria of the ruminant forestomach by hydroxymethylglutarylSCoA reductase inhibitors,” Journal of Dairy Science, vol. 84, no. 6, pp. 1445–1448, 2001.
- M. F. Jahromi, J. B. Liang, M. Rosfarizan, Y. M. Goh, P. Shokryazdan, and Y. W. Ho, “Efficiency of rice straw lignocelluloses degradability by Aspergillus terreus ATCC 74135 in solid state fermentation,” African Journal of Biotechnology, vol. 10, no. 21, pp. 4428–4435, 2011.
- G. S. Lakshmi, C. S. Rao, R. S. Rao, P. J. Hobbs, and R. S. Prakasham, “Enhanced production of xylanase by a newly isolated Aspergillus terreus under solid state fermentation using palm industrial waste: a statistical optimization,” Biochemical Engineering Journal, vol. 48, no. 1, pp. 51–57, 2009.
- J. Gao, H. Weng, D. Zhu, M. Yuan, F. Guan, and Y. Xi, “Production and characterization of cellulolytic enzymes from the thermoacidophilic fungal Aspergillus terreus M11 under solid-state cultivation of corn stover,” Bioresource Technology, vol. 99, no. 16, pp. 7623–7629, 2008.
- M. F. Jahromi, J. B. Liang, Y. W. Ho, M. Rosfarizan, Y. M. Goh, and P. Sokryazdan, “Lovastatin production by Aspergillus terreus using agro-biomass as substrate in solid state fermentation,” Journal of Biomedicine and Biotechnology, vol. 2012, Article ID 196264, 11 pages, 2012.
- W. E. Balch, G. E. Fox, L. J. Magrum et al., “Methanogens: reevaluation of a unique biological group,” Microbiology and Molecular Biology Reviews, vol. 43, no. 2, pp. 260–296, 1979.
- D. R. Lovley, R. C. Greening, and J. G. Ferry, “Rapidly growing rumen methanogenic organism that synthesizes coenzyme M and has a high affinity for formate,” Applied and Environmental Microbiology, vol. 48, no. 1, pp. 81–87, 1984.
- Y. Q. Guo, J. X. Liu, Y. Lu, W. Y. Zhu, S. E. Denman, and C. S. McSweeney, “Effect of tea saponin on methanogenesis, microbial community structure and expression of mcrA gene, in cultures of rumen micro-organisms,” Letters in Applied Microbiology, vol. 47, no. 5, pp. 421–426, 2008.
- K. J. Livak and T. D. Schmittgen, “Analysis of relative gene expression data using real-time quantitative PCR and the 2-[Delta][Delta] CT method,” Methods, vol. 25, no. 4, pp. 402–408, 2001.
- M. A. Hayat, Principles and Techniques of Electron Microscopy: Biological Applications, vol. 4, Cambridge University Press, 2000.
- M. Faseleh Jahromi, J. B. Liang, R. Mohamad, Y. M. Goh, P. Shokryazdan, and Y. W. Ho, “Lovastatin-enriched rice straw enhances biomass quality and suppresses ruminal methanogenesis,” BioMed Research International, vol. 2013, Article ID 397934, 13 pages, 2013.
- SAS, SAS OnlineDoc 9.2. SAS Institute Inc., Cary, NC, USA, 2008.
- E. L. Hendrickson, A. K. Haydock, B. C. Moore, W. B. Whitman, and J. A. Leigh, “Functionally distinct genes regulated by hydrogen limitation and growth rate in methanogenic Archaea,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 21, pp. 8930–8934, 2007.
- B. S. Samuel, E. E. Hansen, J. K. Manchester et al., “Genomic and metabolic adaptations of Methanobrevibacter smithii to the human gut,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 25, pp. 10643–10648, 2007.
- A. W. Alberts, “Discovery, biochemistry and biology of lovastatin,” The American Journal of Cardiology, vol. 62, no. 15, pp. 10–15, 1988.
- A. Smit and A. Mushegian, “Biosynthesis of isoprenoids via mevalonate in Archaea: the lost pathway,” Genome Research, vol. 10, no. 10, pp. 1468–1484, 2000.
- M. S. Chinn, S. E. Nokes, and H. J. Strobel, “Influence of process conditions on end product formation from Clostridium thermocellum 27405 in solid substrate cultivation on paper pulp sludge,” Bioresource Technology, vol. 98, no. 11, pp. 2184–2193, 2007.
- I. G. Macreadie, G. Johnson, T. Schlosser, and P. I. Macreadie, “Growth inhibition of Candida species and Aspergillus fumigatus by statins,” FEMS Microbiology Letters, vol. 262, no. 1, pp. 9–13, 2006.
- H. Mo and C. E. Elson, “Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention,” Experimental Biology and Medicine, vol. 229, no. 7, pp. 567–585, 2004.
- N. van de Donk, M. Kamphuis, H. M. Lokhorst, and A. C. Bloem, “The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells,” Leukemia, vol. 16, no. 7, pp. 1362–1371, 2002.
- K. Howe, F. Sanat, A. E. Thumser, T. Coleman, and N. Plant, “The statin class of HMG-CoA reductase inhibitors demonstrate differential activation of the nuclear receptors PXR, CAR and FXR, as well as their downstream target genes,” Xenobiotica, vol. 41, no. 7, pp. 519–529, 2011.
- M. Jakobisiak, S. Bruno, J. S. Skierski, and Z. Darzynkiewicz, “Cell cycle-specific effects of lovastatin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 9, pp. 3628–3632, 1991.
- J. E. DeClue, W. C. Vass, A. G. Papageorge, D. R. Lowy, and B. M. Willumsen, “Inhibition of cell growth by lovastatin is independent of ras function,” Cancer Research, vol. 51, no. 2, pp. 712–717, 1991.
- K. K. W. Chan, A. M. Oza, and L. L. Siu, “The statins as anticancer agents,” Clinical Cancer Research, vol. 9, no. 1, pp. 10–19, 2003.
- J. Clendening and L. Penn, “Targeting tumor cell metabolism with statins,” Oncogene, vol. 31, no. 48, pp. 4967–4978, 2012.
- Z. Konrad and J. Eichler, “Lipid modification of proteins in Archaea: attachment of a mevalonic acid-based lipid moiety to the surface-layer glycoprotein of Haloferax volcanii follows protein translocation,” Biochemical Journal, vol. 366, part 3, pp. 959–964, 2002.
- K. Conde, S. Roy, H. C. Freake, R. S. Newton, and M. L. Fernandez, “Atorvastatin and simvastatin have distinct effects on hydroxy methylglutaryl-CoA reductase activity and mRNA abundance in the guinea pig,” Lipids, vol. 34, no. 12, pp. 1327–1332, 1999.
- J. L. Song, C. N. Lyons, S. Holleman, B. G. Oliver, and T. C. White, “Antifungal activity of fluconazole in combination with lovastatin and their effects on gene expression in the ergosterol and prenylation pathways in Candida albicans,” Medical Mycology, vol. 41, no. 5, pp. 417–425, 2003.
- M. S. Brown, J. R. Faust, J. L. Goldstein et al., “Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase,” The Journal of Biological Chemistry, vol. 253, no. 4, pp. 1121–1128, 1978.
- M. Nakanishi, J. L. Goldstein, and M. S. Brown, “Multivalent control of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Mevalonate-derived product inhibits translation of mRNA and accelerates degradation of enzyme,” The Journal of Biological Chemistry, vol. 263, no. 18, pp. 8929–8937, 1988.
- J. Wong, C. M. Quinn, I. C. Gelissen, and A. J. Brown, “Endogenous 24(S),25-epoxycholesterol fine-tunes acute control of cellular cholesterol homeostasis,” The Journal of Biological Chemistry, vol. 283, no. 2, pp. 700–707, 2008.
- X. Dong, Y. Xiao, X. Jiang, and Y. Wang, “Quantitative proteomic analysis revealed lovastatin-induced perturbation of cellular pathways in HL-60 cells,” Journal of Proteome Research, vol. 10, no. 12, pp. 5463–5471, 2011.
Copyright © 2013 Mohammad Faseleh Jahromi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.